HOME >> MEDICINE >> NEWS
Duke/Novalon researchers identify potential mechanism behind tamoxifen resistance in breast cancers

DURHAM, N.C. -- Scientists have identified a likely reason why the breast cancer drug tamoxifen stops working in women who use it for more than five years. They say their discovery could lead to new drugs that either work better than tamoxifen or prevent a woman's resistance to the drug.

The researchers, from Duke University Medical Center and Novalon Pharmaceutical Corp., reported in the July 30 issue of Science that tamoxifen initiates a cascade of changes inside the breast cell that are far different from the effects of estrogen or other compounds that rouse the estrogen receptor into action.

Tamoxifen's desired action is to block the effects of estrogen, a hormone involved in the growth of half of all breast cancers. It works by binding to the estrogen receptor and blocking estrogen from docking to it. Hence, tamoxifen has been called an "anti-estrogen." Later, however, tamoxifen begins to lose its effectiveness, and researchers have long wondered why.

Now, they have learned that instead of acting like either an estrogen or an anti-estrogen, tamoxifen has its own distinct properties that drive the cell's estrogen receptor into a different shape than estrogen or other estrogen "mimics" would. The shape the receptor takes determines how the cell will behave and what activity it will generate.

In the case of tamoxifen, the researchers found that it causes the estrogen receptor in breast cells to form an additional and unique "pocket" or surface -- a place where other proteins inside the cell can bind to or dock themselves. While these proteins have yet to be identified, the researchers say their action of binding to this new pocket on the receptor is what changes the cell's response to tamoxifen. For reasons unknown, the cells then begin to see tamoxifen as an estrogen instead of an anti-estrogen, and hence the cancer once again proliferates.

"The implications of our discovering this new pocket fo
'"/>

Contact: Rebecca A. Levine
Levin005@mc.duke.edu
919-684-4148
Duke University Medical Center
30-Jul-1999


Page: 1 2 3 4

Related medicine news :

1. Indiana University researchers closer to helping hearing-impaired using stem cells
2. Protein that helps skin cancer spread identified by Stanford researchers
3. US life expectancy about to decline, researchers say
4. Gene for age-related macular degeneration discovered by Yale researchers
5. Dartmouth researchers find where musical memories are stored in the brain
6. Columbia researchers receive $3 million to combat genetic killer of infants & toddlers
7. US cancer researchers launch first American-Israeli cancer conference
8. USC dental researchers develop first test for predicting cavities in children
9. Young blood revives aging muscles, Stanford researchers find
10. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
11. Age should not be a factor in determining heart transplantation eligibility, researchers say

Post Your Comments:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
Cached News: